JP2023514232A5 - - Google Patents
Info
- Publication number
- JP2023514232A5 JP2023514232A5 JP2022548920A JP2022548920A JP2023514232A5 JP 2023514232 A5 JP2023514232 A5 JP 2023514232A5 JP 2022548920 A JP2022548920 A JP 2022548920A JP 2022548920 A JP2022548920 A JP 2022548920A JP 2023514232 A5 JP2023514232 A5 JP 2023514232A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen
- item
- nucleic acid
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976997P | 2020-02-14 | 2020-02-14 | |
| US62/976,997 | 2020-02-14 | ||
| US202063109831P | 2020-11-04 | 2020-11-04 | |
| US63/109,831 | 2020-11-04 | ||
| PCT/US2021/018027 WO2021163616A1 (en) | 2020-02-14 | 2021-02-12 | Chimeric antigen receptors with cd2 activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514232A JP2023514232A (ja) | 2023-04-05 |
| JP2023514232A5 true JP2023514232A5 (enExample) | 2024-02-21 |
Family
ID=77292741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548920A Pending JP2023514232A (ja) | 2020-02-14 | 2021-02-12 | Ｃｄ２活性化を伴うキメラ抗原受容体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230183312A1 (enExample) |
| EP (1) | EP4103596A4 (enExample) |
| JP (1) | JP2023514232A (enExample) |
| KR (1) | KR20220143057A (enExample) |
| CN (1) | CN115698285A (enExample) |
| AU (1) | AU2021218441A1 (enExample) |
| BR (1) | BR112022014722A2 (enExample) |
| CA (1) | CA3167572A1 (enExample) |
| GB (1) | GB2608729A (enExample) |
| IL (1) | IL295421A (enExample) |
| MX (1) | MX2022009827A (enExample) |
| WO (1) | WO2021163616A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2023217796A1 (en) * | 2022-05-10 | 2023-11-16 | Miltenyi Biotec B.V. & Co. KG | Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy |
| WO2024091848A2 (en) * | 2022-10-25 | 2024-05-02 | The Trustees Of The University Of Pennsylvania | Anti-ceacam6 car-t cells for the treatment of ceacam6+ tumors |
| EP4713467A1 (en) * | 2023-05-15 | 2026-03-25 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| EP4724486A1 (en) * | 2023-06-06 | 2026-04-15 | Molecular Partners AG | Recombinant cd2 binding proteins and their use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| WO2013126729A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
| RU2658485C2 (ru) * | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
| DK4074735T3 (da) * | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| HRP20191873T1 (hr) * | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| US9777064B2 (en) * | 2015-03-17 | 2017-10-03 | Chimera Bioengineering, Inc. | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof |
| WO2017024318A1 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| EP3535423B1 (en) * | 2016-11-07 | 2022-01-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods for selecting therapy for a cancer patient |
| EP3568416A4 (en) * | 2017-01-13 | 2020-07-08 | Celdara Medical, LLC | TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| WO2019028051A1 (en) * | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY |
| ES2960419T3 (es) * | 2017-09-15 | 2024-03-04 | Lentigen Tech Inc | Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19 |
| US12473342B2 (en) * | 2018-04-27 | 2025-11-18 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis |
-
2021
- 2021-02-12 MX MX2022009827A patent/MX2022009827A/es unknown
- 2021-02-12 JP JP2022548920A patent/JP2023514232A/ja active Pending
- 2021-02-12 WO PCT/US2021/018027 patent/WO2021163616A1/en not_active Ceased
- 2021-02-12 KR KR1020227031318A patent/KR20220143057A/ko active Pending
- 2021-02-12 IL IL295421A patent/IL295421A/en unknown
- 2021-02-12 US US17/904,219 patent/US20230183312A1/en active Pending
- 2021-02-12 EP EP21754453.5A patent/EP4103596A4/en active Pending
- 2021-02-12 GB GB2213361.5A patent/GB2608729A/en not_active Withdrawn
- 2021-02-12 BR BR112022014722A patent/BR112022014722A2/pt unknown
- 2021-02-12 CA CA3167572A patent/CA3167572A1/en active Pending
- 2021-02-12 AU AU2021218441A patent/AU2021218441A1/en active Pending
- 2021-02-12 CN CN202180026973.0A patent/CN115698285A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514232A5 (enExample) | ||
| US11807691B2 (en) | Compositions and methods for treatment of cancer | |
| GB2608729A (en) | Chimeric antigen receptors with CD2 activation | |
| US20230016031A1 (en) | Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) thereapy | |
| US11530264B2 (en) | Multifunctional protein | |
| JP2020530989A5 (enExample) | ||
| JP2017500869A5 (enExample) | ||
| WO2018156802A1 (en) | Compositions and methods for treatment of cancer | |
| JP2018516092A5 (enExample) | ||
| US20210154233A1 (en) | MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY | |
| WO2018045034A1 (en) | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain | |
| JP2021530971A (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| CA3132204A1 (en) | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof | |
| CN115667317A (zh) | 全人源的靶向cd19和cd22双特异抗原嵌合受体及其应用 | |
| AU2025204510A9 (en) | Car library and scFv manufacturing method | |
| JP2022526720A5 (enExample) | ||
| JP2022532994A (ja) | がんの治療のための組成物及び方法 | |
| CN119744270A (zh) | 一种异源二聚体融合蛋白及其应用 | |
| US20240226294A9 (en) | Customized chimeric antigen receptor polypeptides | |
| US20250313622A1 (en) | Chimeric antigen receptor (car) constructs with nk receptor signaling domain | |
| WO2025096305A1 (en) | Chimeric antigen receptors with a tip co-stimulatory domain | |
| WO2023225641A2 (en) | Compositions and methods for targeting clec12a-expressing cancers | |
| WO2023245042A2 (en) | Nkg2d expressing car-t cells | |
| WO2025198540A1 (en) | Decorin-secreting chimeric antigen receptor immune cells | |
| WO2024210072A1 (ja) | キメラタンパク質、核酸、ベクター、ｔ細胞又はｎｋ細胞、医薬組成物、組み合わせ物、組み合わせ医薬、及び標的抗原結合タンパク質 |